UY30925A1 - Proteinas de fusion de inmunoglobulina y metodos de elaboracion - Google Patents

Proteinas de fusion de inmunoglobulina y metodos de elaboracion

Info

Publication number
UY30925A1
UY30925A1 UY30925A UY30925A UY30925A1 UY 30925 A1 UY30925 A1 UY 30925A1 UY 30925 A UY30925 A UY 30925A UY 30925 A UY30925 A UY 30925A UY 30925 A1 UY30925 A1 UY 30925A1
Authority
UY
Uruguay
Prior art keywords
fusion proteins
immunoglobulin fusion
immunoglobulin
elaboration
methods
Prior art date
Application number
UY30925A
Other languages
English (en)
Inventor
Jeffrey C Webster
Ye Edward Tian
Robert Rothlein
Adnan M M Mjalli
Original Assignee
Transtech Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma filed Critical Transtech Pharma
Publication of UY30925A1 publication Critical patent/UY30925A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En ciertas materializaciones, la proteína de fusion puede incluir un polipéptido no inmunoglobulina unido a un polipéptido inmunoglobulina. En ciertas materializaciones, el polipéptido no inmunoglobulina puede incluir una region bisagra Fc de inmunoglobulina, pero que permite la union correcta de las cadenas de inmunoglobulina.
UY30925A 2007-02-15 2008-02-15 Proteinas de fusion de inmunoglobulina y metodos de elaboracion UY30925A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90154007P 2007-02-15 2007-02-15

Publications (1)

Publication Number Publication Date
UY30925A1 true UY30925A1 (es) 2008-09-30

Family

ID=39690682

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30925A UY30925A1 (es) 2007-02-15 2008-02-15 Proteinas de fusion de inmunoglobulina y metodos de elaboracion

Country Status (6)

Country Link
US (2) US20080199467A1 (es)
AR (1) AR065373A1 (es)
CL (1) CL2008000460A1 (es)
TW (1) TW200848071A (es)
UY (1) UY30925A1 (es)
WO (1) WO2008100470A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3192872A1 (en) 2003-08-26 2017-07-19 The Regents of the University of Colorado, a body corporate Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
EA012586B1 (ru) * 2004-08-03 2009-10-30 Транстек Фарма, Инк. Rage-слитые белки и способы их применения
NZ552128A (en) 2004-08-03 2009-09-25 Transtech Pharma Inc Rage fusion proteins without Fc hinge region and methods of use
AU2006327353B2 (en) * 2005-12-23 2011-11-24 Gcoder Systems Ab Positioning pattern
BRPI0707640A2 (pt) * 2006-02-09 2011-05-10 Transtech Pharma Inc proteÍnas de fusço do rage e mÉtodos de uso
NZ571692A (en) 2006-05-05 2012-01-12 Transtech Pharma Inc Rage fusion proteins, formulations, and methods of use thereof
US20080199467A1 (en) * 2007-02-15 2008-08-21 Mjalli Adnan M M Immunoglobulin fusion proteins and methods of making
AU2008265983B2 (en) 2007-06-14 2013-06-20 Galactica Pharmaceuticals, Inc. RAGE fusion proteins
CN101977932B (zh) 2008-01-31 2014-09-03 美国政府健康及人类服务部 工程化抗体恒定结构域分子
AU2010240569A1 (en) 2009-04-20 2011-10-20 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
EP2723370A4 (en) 2011-06-24 2015-06-03 Univ Colorado Regents COMPOSITIONS, PROCESS AND USE OF ALPHA-1-ANTITRYPHIN FUSION MOLECULES
EP2802653A4 (en) * 2012-01-10 2015-09-02 Univ Colorado Regents ALPHA-1 ANTITRYPSIN FUSION MOLECULE COMPOSITIONS, METHODS AND USES THEREOF
JP2019515904A (ja) * 2016-04-14 2019-06-13 アイコニック セラピューティクス，インコーポレイテッド 新血管新生に関連する障害を治療するための組成物および方法
EP3483180A1 (en) * 2017-11-14 2019-05-15 Affilogic Multi specific molecules

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
WO1996022095A2 (en) * 1995-01-18 1996-07-25 Alteon Inc. Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts
FI119756B (fi) * 1995-01-18 2009-03-13 Alteon Inc Tiatsoliumyhdisteiden käyttö pitkälle edenneen glykosylaation lopputuotteiden muodostumisen estossa ja suunnan muutoksessa
US5656261A (en) * 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
EP0827511A1 (en) * 1995-04-05 1998-03-11 The Picower Institute For Medical Research Agents for binding to advanced glycosylation endproducts, and methods of their use
US5747035A (en) * 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US7081241B1 (en) * 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
WO2000020621A1 (en) * 1998-10-06 2000-04-13 The Trustees Of Columbia University In The City Of New York Extracellular novel rage binding protein (en-rage) and uses thereof
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
MY131805A (en) * 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
US6380165B1 (en) * 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
US6753150B2 (en) * 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
NZ511055A (en) * 1998-10-05 2003-10-31 Pharmexa As Novel methods for therapeutic vaccination
US6197294B1 (en) * 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
US6787566B2 (en) * 1999-04-05 2004-09-07 City Of Hope Breakers of advanced glycation endproducts
US6605642B2 (en) * 1999-04-05 2003-08-12 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGES)
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
AU6766800A (en) * 1999-08-13 2001-03-13 Trustees Of Columbia University In The City Of New York, The Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof
US20050170382A1 (en) * 1999-10-06 2005-08-04 The Trustees Of Columbia University In The City Of New York. RAGE-related compositions
JP2003516150A (ja) * 1999-12-08 2003-05-13 ジェンセット 潜在性分泌タンパク質をコードする全長ヒトｃＤＮＡ
MXPA02010194A (es) * 2000-04-14 2004-08-19 Niadyne Corp Metodo para identificar reguladores de formacion de proteina-producto final de glicacion avanzada (proteina-age).
US6908741B1 (en) * 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US6825164B1 (en) * 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
US6563015B1 (en) * 2000-08-14 2003-05-13 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof
WO2002029091A2 (en) * 2000-10-02 2002-04-11 Reddy Us Therapeutics, Inc. Methods and compositions for the treatment of inflammatory diseases
WO2002030889A2 (en) * 2000-10-13 2002-04-18 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
US20050244849A1 (en) * 2000-12-15 2005-11-03 Genetics Institute, Llc Screening assays for rheumatoid arthritis
JP2005501222A (ja) * 2000-12-29 2005-01-13 レディ ユーエス セラピューティクス インコーポレイテッド 炎症応答を調節する化合物を検出するための方法及び組成物
JP2004532620A (ja) * 2001-02-19 2004-10-28 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 免疫原性の低減された人工タンパク質
JP3837494B2 (ja) * 2001-03-19 2006-10-25 国立大学法人金沢大学 可溶型ｒａｇｅタンパク質
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
JP2006512900A (ja) * 2002-08-16 2006-04-20 ワイス Ｒａｇｅ関連疾患の治療用組成物及び方法
WO2004100890A2 (en) * 2003-05-09 2004-11-25 The Trustees Of Columbia University In The City Of New York Rage g82s-related methods and compositions for treating inflammatory disorders
CA2522275A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
US20050008649A1 (en) * 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
JP2007504247A (ja) * 2003-09-05 2007-03-01 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 糸球体損傷を治療するためのｒａｇｅに関連した方法および組成物
US20070167360A1 (en) * 2003-10-31 2007-07-19 Yan Shi D Methods for treating multiple sclerosis
US7151400B2 (en) * 2004-07-13 2006-12-19 Taiwan Semiconductor Manufacturing Company, Ltd. Boost-biased level shifter
EP1771565B1 (en) * 2004-07-20 2012-09-05 The Feinstein Institute for Medical Research Rage protein derivatives
NZ552128A (en) * 2004-08-03 2009-09-25 Transtech Pharma Inc Rage fusion proteins without Fc hinge region and methods of use
EA012586B1 (ru) * 2004-08-03 2009-10-30 Транстек Фарма, Инк. Rage-слитые белки и способы их применения
JP2008537874A (ja) * 2004-09-27 2008-10-02 セントカー・インコーポレーテツド ｓＲＡＧＥミメティボディ、組成物、方法および使用
US20080207499A1 (en) * 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
BRPI0707640A2 (pt) * 2006-02-09 2011-05-10 Transtech Pharma Inc proteÍnas de fusço do rage e mÉtodos de uso
NZ571692A (en) * 2006-05-05 2012-01-12 Transtech Pharma Inc Rage fusion proteins, formulations, and methods of use thereof
US20080199467A1 (en) * 2007-02-15 2008-08-21 Mjalli Adnan M M Immunoglobulin fusion proteins and methods of making

Also Published As

Publication number Publication date
AR065373A1 (es) 2009-06-03
US20110110945A1 (en) 2011-05-12
WO2008100470A2 (en) 2008-08-21
WO2008100470A3 (en) 2008-12-24
TW200848071A (en) 2008-12-16
CL2008000460A1 (es) 2008-08-22
US20080199467A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
UY30925A1 (es) Proteinas de fusion de inmunoglobulina y metodos de elaboracion
EA201390923A1 (ru) Модифицированное антитело с улучшенным полупериодом существования
TW200732350A (en) Methods for generating monovalent IgG
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
CR20110400A (es) Proteinas de enlace al receptor cgrp humano
CR20120210A (es) Proteínas de enlace al antigeno il-23 humanas
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
BR122018016045B8 (pt) proteína variante otimizada
MX2019009817A (es) Anticuerpos anti-tau y metodos de uso de los mismos.
EA201792442A1 (ru) Биспецифические агенты, связывающие простатический специфический мембранный антиген (psma), и их применение
CR11282A (es) Proteinas enlazadas al antigeno de celula de cepa mcdonough de felino humanas
AR057614A1 (es) Composiciones y metodos para producir moleculas de union con antigeno hibridas y usos de las mismas
ECSP088733A (es) Anticuerpos anti-5t4 y usos de los mismos
NO20091064L (no) Antistoffer mot IL-17A
CR20120105A (es) Proteínas terapéuticas de unión a dll4
BRPI0716744A2 (pt) proteínas de fusão de albumina
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
DK3002298T3 (da) Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf
DK1960434T3 (da) Monoklonale, humane antistoffer mod Fucosyl-GM1 og fremgangsmåder til anvendelse af anti-Fucosyl-GM1
UY30324A1 (es) Proteinas de fusion del rage, formulaciones y métodos de uso
MX354904B (es) Uso combinado de proteínas cry1ca y cry1fa para el manejo de la resistencia de insectos.
ATE455127T1 (de) Humane anti-humane cd3-bindungsmoleküle

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170912